Follow-on Biologics Showdown In House Set For July 17
This article was originally published in The Pink Sheet Daily
Executive Summary
House tri-committee bill is silent on follow-on biologics, but Rep. Anna Eshoo wants to be heard. Can the germaneness rule save Rep. Waxman from defeat?
You may also be interested in...
And Then There Were 12: Follow-on Biologics Picture Coming Into Focus
It almost seems like the conference committee negotiations for follow-on biologics legislation have begun, but the two actors that the generic industry expects to best represent its issues - Rep. Henry Waxman, D-Calif., and President Obama - are not at the table
And Then There Were 12: Follow-on Biologics Picture Coming Into Focus
It almost seems like the conference committee negotiations for follow-on biologics legislation have begun, but the two actors that the generic industry expects to best represent its issues - Rep. Henry Waxman, D-Calif., and President Obama - are not at the table
Follow-on Biologics: Rep. Eshoo Revising Her Bill To Be Closer To Senate Provision
California Democrat drops data exclusivity to 12 years, plus six months for pediatric studies, and removes requirement for FDA guidance before approval.